CSPC Pharmaceutical Group Limited has announced an exclusive license agreement with Cipla USA, Inc. for the commercialization of its Irinotecan Liposome Injection in the United States. Under the terms of the agreement, CSPC will receive an upfront payment of $15 million, with potential additional payments of up to $1,050 million based on commercial and regulatory milestones, along with tiered double-digit royalties on annual net sales. The product, developed under CSPC's liposome technology platform, is used in the treatment of multiple solid tumors. This move marks a significant step in CSPC's expansion into the U.S. market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.